GLENMARK LIFE SCIENCES
|
GLENMARK LIFE SCIENCES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 38.43 | 38.11 | 34.17 | 358.76 | 1,597.44 |
| CEPS(Rs) | 42.79 | 41.55 | 37.27 | 35.71 | 31.77 |
| DPS(Rs) | 22.50 | 21.00 | 21.00 | - | - |
| Book NAV/Share(Rs) | 189.45 | 173.97 | 167.38 | 768.11 | 2,049.45 |
| Tax Rate(%) | 25.41 | 25.72 | 25.88 | 25.35 | 25.64 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 29.44 | 29.56 | 28.98 | 31.28 | 30.66 |
| EBIT Margin(%) | 27.64 | 28.96 | 27.89 | 29.55 | 29.53 |
| Pre Tax Margin(%) | 27.57 | 28.93 | 26.58 | 24.92 | 27.35 |
| PAT Margin (%) | 20.56 | 21.49 | 19.70 | 18.60 | 20.34 |
| Cash Profit Margin (%) | 22.90 | 23.43 | 21.48 | 20.37 | 22.25 |
| Performance Ratios | |||||
| ROA(%) | 13.96 | 15.43 | 16.57 | 17.82 | 19.56 |
| ROE(%) | 21.15 | 22.33 | 29.87 | 60.91 | 127.84 |
| ROCE(%) | 28.31 | 30.01 | 42.24 | 96.75 | 185.60 |
| Asset Turnover(x) | 0.68 | 0.72 | 0.84 | 0.96 | 0.96 |
| Sales/Fixed Asset(x) | 2.35 | 2.65 | 3.13 | 3.03 | 2.88 |
| Working Capital/Sales(x) | 1.55 | 1.60 | 1.54 | 10.64 | -10.45 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.43 | 0.38 | 0.32 | 0.33 | 0.35 |
| Receivable days | 125.30 | 124.34 | 111.01 | 121.50 | 128.84 |
| Inventory Days | 101.28 | 94.11 | 88.40 | 89.45 | 96.46 |
| Payable days | 149.95 | 136.29 | 94.72 | 87.85 | 105.53 |
| Valuation Parameters | |||||
| PER(x) | 20.17 | 10.28 | 13.43 | - | - |
| PCE(x) | 18.12 | 9.43 | 12.32 | - | - |
| Price/Book(x) | 4.09 | 2.25 | 2.74 | - | - |
| Yield(%) | 2.90 | 5.36 | 4.58 | - | - |
| EV/Net Sales(x) | 4.03 | 2.08 | 2.41 | -0.06 | -0.01 |
| EV/Core EBITDA(x) | 13.40 | 6.69 | 8.10 | -0.19 | -0.02 |
| EV/EBIT(x) | 14.53 | 7.13 | 8.62 | -0.20 | -0.02 |
| EV/CE(x) | 3.94 | 2.10 | 1.80 | -0.05 | - |
| M Cap / Sales | 4.16 | 2.22 | 2.65 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.64 | 1.79 | 12.63 | 22.63 | 73.43 |
| Core EBITDA Growth(%) | 2.24 | 6.42 | 6.57 | 22.30 | 95.01 |
| EBIT Growth(%) | 0.58 | 6.12 | 6.16 | 22.86 | 98.59 |
| PAT Growth(%) | 0.84 | 11.52 | 19.10 | 12.29 | 60.08 |
| EPS Growth(%) | 0.84 | 11.52 | -90.47 | -77.54 | 60.08 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 4.37 | 2.33 | 2.85 | 1.12 | 0.89 |
| Quick Ratio(x) | 2.85 | 1.74 | 2.16 | 0.77 | 0.57 |
| Interest Cover(x) | 409.34 | 1,150.19 | 21.20 | 6.38 | 13.56 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLENMARK LIFE SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK LIFE SCIENCES | ₹13,244.1 Cr | 1.9% | -2.7% | 71.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,518.0 Cr | -0.1% | -6.3% | 49.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹158,636.0 Cr | 3.5% | 0.9% | 66.2% | Stock Analytics | |
| CIPLA | ₹118,368.0 Cr | -2.6% | -3.8% | 19.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,671.4 Cr | -4.1% | -10.8% | 9.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,013.6 Cr | -2% | -6.1% | 49.9% | Stock Analytics | |
GLENMARK LIFE SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK LIFE SCIENCES | 1.9% |
-2.7% |
71.4% |
| SENSEX | -1.9% |
-5% |
17.5% |
You may also like the below Video Courses
